SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-24-017571
Filing Date
2024-02-21
Accepted
2024-02-21 07:50:50
Documents
107
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 10-K crsp-20231231.htm   iXBRL 10-K 3441100
2 EX-4.1 crsp-ex4_1.htm EX-4.1 25267
3 EX-21.1 crsp-ex21_1.htm EX-21.1 5826
4 EX-23.1 crsp-ex23_1.htm EX-23.1 6679
5 EX-31.1 crsp-ex31_1.htm EX-31.1 12396
6 EX-31.2 crsp-ex31_2.htm EX-31.2 12374
7 EX-32.1 crsp-ex32_1.htm EX-32.1 10476
8 EX-97.1 crsp-ex97_1.htm EX-97.1 36806
9 GRAPHIC img133321815_0.jpg GRAPHIC 5959
10 GRAPHIC img168450911_0.jpg GRAPHIC 272537
11 GRAPHIC img168450911_1.jpg GRAPHIC 484914
12 GRAPHIC img168450911_2.jpg GRAPHIC 150330
13 GRAPHIC img168450911_3.jpg GRAPHIC 609754
14 GRAPHIC img168450911_4.jpg GRAPHIC 661929
15 GRAPHIC img168450911_5.jpg GRAPHIC 225734
16 GRAPHIC img168450911_6.jpg GRAPHIC 336661
17 GRAPHIC img168450911_7.jpg GRAPHIC 156957
18 GRAPHIC img168450911_8.jpg GRAPHIC 112426
19 GRAPHIC img168450911_9.jpg GRAPHIC 251131
20 GRAPHIC img168450911_10.jpg GRAPHIC 201580
21 GRAPHIC img168450911_11.jpg GRAPHIC 117567
22 GRAPHIC img168450911_12.jpg GRAPHIC 274665
23 GRAPHIC img168450911_13.jpg GRAPHIC 345951
24 GRAPHIC img168450911_14.jpg GRAPHIC 43078
  Complete submission text file 0000950170-24-017571.txt   23219672

Data Files

Seq Description Document Type Size
25 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT crsp-20231231.xsd EX-101.SCH 1691533
109 EXTRACTED XBRL INSTANCE DOCUMENT crsp-20231231_htm.xml XML 2312825
Mailing Address BAARERSTRASSE 14 ZUG V8 CH-6300
Business Address BAARERSTRASSE 14 ZUG V8 CH-6300 6173154600
CRISPR Therapeutics AG (Filer) CIK: 0001674416 (see all company filings)

IRS No.: 473173478 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-37923 | Film No.: 24656410
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)